{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-102971","form_type":"8-K","ticker":null,"cik":"0001827506","company_name":"Tourmaline Bio, Inc.","filed_at":"2025-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.653163+00:00","generated_at":"2026-05-17T01:58:47.911458+00:00","sec_items":["1.02","2.01","3.01","5.01","5.03","3.03","5.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Tourmaline Bio acquired by Novartis for $48/share; stock to be delisted","bullets":["Tender offer completed with 92.94% of shares tendered (24,030,382 shares).","Merger effected under DGCL Section 251(h); all remaining shares converted to $48 cash each.","All outstanding stock options and RSUs cashed out at same per-share value.","All prior directors and officers resigned; Novartis appointees John McKenna and Eduard Marti now lead.","Stock to be delisted from Nasdaq; deregistration to follow."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-102971","json":"https://secwatch.observer/filing/0001104659-25-102971.json","markdown":"https://secwatch.observer/filing/0001104659-25-102971.md","text":"https://secwatch.observer/filing/0001104659-25-102971.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1827506/000110465925102971/0001104659-25-102971-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1827506/000110465925102971/tm2529486d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:58:47.911458+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9309fdf0d739a9cea9691df02f69cc3f0906d924","claim":"Tourmaline Bio, Inc.: Certificate of incorporation amended and restated in its entirety pursuant to Merger Agreement.","evidence_excerpt":"the certificate of incorporation of the Company (the “ Certificate of Incorporation ”) was amended and restated in its entirety","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1827506/000110465925102971/0001104659-25-102971-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"df46b0584f50228d0468992c6160305b6debe4cf","claim":"Tourmaline Bio, Inc.: Bylaws amended and restated in their entirety pursuant to Merger Agreement.","evidence_excerpt":"the Company’s bylaws (the “ Bylaws ”) were amended and restated in their entirety","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1827506/000110465925102971/0001104659-25-102971-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}